Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiomyopathy
Biotech
Merck KGaA pledges $50M to new biotech with eye to acquisition
The cash will power Saturnus Bio's research into genetic heart diseases, with Merck KGaA holding the exclusive right to buy the NewCo down the line.
Darren Incorvaia
Jun 23, 2026 10:16am
Edgewise data power rival to BMS and Cytokinetics toward phase 3
Jun 16, 2026 10:39am
Why Lexicon is in ‘good shape to go crazy’: CEO
May 13, 2026 10:50am
Cytokinetics doesn't want Big Pharma help to overtake Camzyos
Nov 18, 2025 1:30pm
FDA puts Tenaya heart disease gene therapy trial on hold
Nov 10, 2025 5:16am
Braveheart, with Biogen CEO on board, rallies $185M series A
Nov 5, 2025 7:51am
